CA3071055A1 - Reprogramming of somatic cells - Google Patents

Reprogramming of somatic cells Download PDF

Info

Publication number
CA3071055A1
CA3071055A1 CA3071055A CA3071055A CA3071055A1 CA 3071055 A1 CA3071055 A1 CA 3071055A1 CA 3071055 A CA3071055 A CA 3071055A CA 3071055 A CA3071055 A CA 3071055A CA 3071055 A1 CA3071055 A1 CA 3071055A1
Authority
CA
Canada
Prior art keywords
cells
cell
reprogramming
somatic
somatic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071055A
Other languages
English (en)
French (fr)
Inventor
Rudolph Jaenisch
Jacob Hanna
Marius Wernig
Christopher Lengner
Alexander Meissner
Oliver Tobias Brambrink
G. Grant Welstead
Ruth Foreman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of CA3071055A1 publication Critical patent/CA3071055A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)
CA3071055A 2007-04-07 2008-04-07 Reprogramming of somatic cells Pending CA3071055A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92212107P 2007-04-07 2007-04-07
US60/922,121 2007-04-07
US95934107P 2007-07-12 2007-07-12
US60/959,341 2007-07-12
US3606508P 2008-03-12 2008-03-12
US61/036,065 2008-03-12
CA2683056A CA2683056C (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2683056A Division CA2683056C (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Publications (1)

Publication Number Publication Date
CA3071055A1 true CA3071055A1 (en) 2008-10-16

Family

ID=39831277

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3071055A Pending CA3071055A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells
CA2683056A Active CA2683056C (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2683056A Active CA2683056C (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Country Status (9)

Country Link
US (5) US9382515B2 (enExample)
EP (3) EP3878949B1 (enExample)
JP (8) JP2010523117A (enExample)
CN (2) CN105861443A (enExample)
AU (1) AU2008236629B2 (enExample)
CA (2) CA3071055A1 (enExample)
MX (2) MX348010B (enExample)
RU (1) RU2502799C2 (enExample)
WO (1) WO2008124133A1 (enExample)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
KR101004634B1 (ko) 2005-08-01 2011-01-04 뉴포텐셜, 인크. 잠재력이 복원된 리프로그래밍된 세포의 제조
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009032194A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
EP2227241A1 (en) * 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
AU2008329563A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Oct4 protein
JP5626619B2 (ja) * 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
KR101532442B1 (ko) * 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
CN102083982A (zh) * 2008-04-07 2011-06-01 纽珀滕索有限公司 通过rna干扰引入复能基因而重编程细胞
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
WO2009152529A2 (en) 2008-06-13 2009-12-17 Whitehead Institute For Biomedical Research Nine Cambridge Center Programming and reprogramming of cells
US9238797B2 (en) 2008-07-07 2016-01-19 Takara Bio Inc. Method for production of pluripotent stem cell
WO2010027062A1 (ja) * 2008-09-04 2010-03-11 独立行政法人理化学研究所 B細胞由来iPS細胞およびその用途
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
WO2010056808A2 (en) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
CN102245588B (zh) 2008-12-23 2016-05-04 塞格提斯有限公司 缩酮酰胺化合物、其制备方法及应用
CA2753845C (en) * 2009-02-27 2019-10-29 Kyoto University Nuclear reprogramming substance comprising glis1
WO2010105311A1 (en) * 2009-03-20 2010-09-23 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
EP2421956A4 (en) * 2009-04-24 2013-10-02 Whitehead Biomedical Inst COMPOSITIONS AND METHODS FOR OBTAINING OR CULTURING PLURIPOTENTER CELLS
JP5886195B2 (ja) 2009-07-09 2016-03-16 ホワイトヘッド・インスティチュート・フォア・バイオメディカル・リサーチ 哺乳動物遺伝学のための組成物および方法、ならびにその使用
EP2468312A4 (en) 2009-08-19 2014-05-14 Univ Tohoku FOIL FOR CORNEAL TRANSPLANTS
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
AU2010312291A1 (en) * 2009-10-29 2012-06-21 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
US9696297B2 (en) * 2009-12-23 2017-07-04 Salk Institute For Biological Studies Method for preparing an X chromosome inactivated female human neural cell
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP2601289B1 (en) 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
CN103459611B (zh) 2010-09-17 2016-11-02 哈佛大学校长及研究员协会 对多能干细胞的效用和安全性进行表征的功能基因组学研究
WO2012060473A1 (en) 2010-11-04 2012-05-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
JP6029137B2 (ja) 2010-12-03 2016-11-24 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
JP6273842B2 (ja) * 2011-02-25 2018-02-07 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法
CN102731653B (zh) * 2011-04-06 2013-12-11 李凌松 一种抗磷酸化Oct4蛋白的抗体及其应用
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP3260140B1 (en) 2011-12-05 2021-02-03 Factor Bioscience Inc. Methods and products for transfecting cells
CN104781396A (zh) * 2012-01-17 2015-07-15 小利兰·斯坦福大学托管委员会 用于体细胞核重编程的先天免疫激活
AU2013251649B2 (en) 2012-04-24 2019-04-04 Vcell Therapeutics, Inc. Generating pluripotent cells de novo
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
US20150267174A1 (en) 2012-10-09 2015-09-24 Nakanobu Hayashi Reprogramming peptide and use thereof
EP2912178B1 (en) 2012-10-25 2020-06-17 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
CA3106271A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014249148B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
EP2971056A4 (en) 2013-03-15 2016-11-23 Whitehead Biomedical Inst CELLULAR DISCOVERY PLATFORM FOR NEURODEGENERATIVE DISEASES
CN105531365A (zh) 2013-04-23 2016-04-27 耶达研究及发展有限公司 分离的幼稚多能干细胞和产生所述细胞的方法
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
US11085067B2 (en) 2013-06-10 2021-08-10 President And Fellows Of Harvard College Early developmental genomic assay for characterizing pluripotent stem cell utility and safety
JP6611170B2 (ja) 2013-09-12 2019-11-27 株式会社カネカ 人工多能性幹細胞の分化誘導方法及び選別方法
US11767507B2 (en) 2013-11-08 2023-09-26 The Mclean Hospital Corporation Methods for efficient generation of GABAergic interneurons from pluripotent stem cells
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
ES2895941T3 (es) 2014-02-10 2022-02-23 Univ Leland Stanford Junior Activación de la inmunidad innata para una reprogramación nuclear mejorada de células somáticas con ARNm
JP2017513517A (ja) 2014-03-19 2017-06-01 ブイセル セラピューティックス，インコーポレイテッド 多能性細胞に関連する方法
CN122465832A (zh) 2014-07-30 2026-07-28 耶达研究及发展有限公司 用于培养多能干细胞的培养基
EP3191578B1 (en) 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10961532B2 (en) * 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
EP3283127B1 (en) * 2015-04-15 2020-02-26 University of Massachusetts Compositions and methods for xi chromosome reactivation
US20180066223A1 (en) 2015-04-17 2018-03-08 Xcell Biosciences, Inc. Cancer cell enrichment system
WO2016172734A1 (en) 2015-04-24 2016-10-27 California Institute Of Technology Reactivation of x chromosome genes
US20170044609A1 (en) * 2015-04-24 2017-02-16 California Institute Of Technology Reactivation of x chromosome genes
BR112018001232A2 (pt) 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
WO2017044853A1 (en) * 2015-09-09 2017-03-16 Trustees Of Tufts College Methods of generating neural stem cells
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105624117A (zh) * 2016-01-18 2016-06-01 哈尔滨医科大学 一种低氧促进小鼠成纤维细胞重编程为心肌细胞的方法
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2017223199A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
MX2019002004A (es) 2016-08-19 2019-10-09 Whitehead Inst Biomedical Res Metodos para editar la metilacion del adn.
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CN106544315A (zh) * 2016-10-12 2017-03-29 广东艾时代生物科技有限责任公司 一种脂肪间充质干细胞诱导成多能干细胞的方法
JP2019537427A (ja) 2016-10-27 2019-12-26 カリフォルニア インスティチュート オブ テクノロジー Ｘ染色体の再活性化のためのｈｄａｃ阻害剤組成物
US11944719B2 (en) 2016-12-16 2024-04-02 Iviva Medical, Inc. Thin film interposition of basement membrane scaffolds
US11873496B2 (en) 2017-01-09 2024-01-16 Whitehead Institute For Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
US11345891B2 (en) * 2017-04-05 2022-05-31 Asgard Therapeutics Ab Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
EP3640318A4 (en) 2017-06-14 2021-03-17 Takeda Pharmaceutical Company Limited CELL SEALING DEVICE
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
KR20200091885A (ko) 2017-11-30 2020-07-31 고쿠리츠 다이가쿠 호진 교토 다이가쿠 세포의 배양 방법
PL241125B1 (pl) 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
TWI821230B (zh) 2017-12-22 2023-11-11 日商千紙鶴治療公司 細胞培養裝置、培養液吸引器及細胞培養方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
TW201945536A (zh) 2018-03-19 2019-12-01 國立大學法人京都大學 水凝膠膠囊
CN111971392A (zh) 2018-03-30 2020-11-20 国立大学法人京都大学 细胞的制造方法
JP7257698B2 (ja) 2018-03-30 2023-04-14 オリヅルセラピューティクス株式会社 複素環化合物
JP7344486B2 (ja) 2018-03-30 2023-09-14 国立大学法人京都大学 心筋細胞成熟促進剤
AU2019261083B2 (en) 2018-04-23 2025-01-23 Orizuru Therapeutics, Inc. Growth inhibitor
CN112912490B (zh) 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
JP7436990B2 (ja) 2018-08-10 2024-02-22 国立大学法人京都大学 カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
JP7382603B2 (ja) 2018-08-10 2023-11-17 国立大学法人京都大学 Ｃｄ３陽性細胞の製造方法
MX2021002018A (es) 2018-08-22 2021-07-15 Univ Kyoto Metodo para producir precursores neurales entericos.
EA202190624A1 (ru) 2018-08-31 2021-06-09 Нойл-Иммьюн Байотек, Инк. Car-экспрессирующие т-клетки и car-экспрессирующий вектор
TWI862513B (zh) 2018-09-19 2024-11-21 日商千紙鶴治療公司 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法
WO2020061591A1 (en) 2018-09-21 2020-03-26 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins
JP7553918B2 (ja) 2018-10-15 2024-09-19 公立大学法人横浜市立大学 栄養組成物
JP7542822B2 (ja) 2018-12-27 2024-09-02 国立大学法人京都大学 Ｔ細胞受容体の改変体
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
WO2020158914A1 (ja) 2019-02-01 2020-08-06 国立大学法人京都大学 細胞の検出方法
JP7533896B2 (ja) 2019-03-29 2024-08-14 公立大学法人横浜市立大学 スクリーニング方法および毒性評価法
KR102939973B1 (ko) 2019-04-10 2026-03-16 오리즈루 세라퓨틱스 가부시키가이샤 생체 조직형 구조체의 제조 방법
EP3969571A4 (en) 2019-05-14 2023-05-24 Aleph Farms Ltd. PLURIPOTENTE CELL AGGREGATES AND THEIR USE
JP7541700B2 (ja) 2019-06-11 2024-08-29 国立大学法人京都大学 腎間質細胞の製造方法
CA3145425A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4019549B1 (en) 2019-08-20 2025-06-04 Orizuru Therapeutics, Inc. Method for enriching cardiac myocytes
TW202130805A (zh) 2019-10-21 2021-08-16 日商武田藥品工業股份有限公司 增生抑制劑
AR120348A1 (es) 2019-11-01 2022-02-09 Univ Kyoto Método para producir células t
BR112022009181A2 (pt) 2019-11-25 2022-07-26 Univ Kyoto Sistema para prover um produto de célula t, métodos para produzir um produto de célula t, para construir um banco celular e uma coleção de produto de célula t e para prover um produto de célula t, banco celular, coleções de banco celular e de produto de célula t, e, produto de célula t
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
WO2021187601A1 (ja) 2020-03-19 2021-09-23 国立大学法人京都大学 心筋細胞の精製方法
WO2021200901A1 (ja) 2020-03-31 2021-10-07 国立大学法人京都大学 Ｔ前駆細胞の製造方法
JPWO2021241668A1 (enExample) 2020-05-28 2021-12-02
CN112201307B (zh) * 2020-09-23 2024-09-17 温州医科大学 一种转录本注释方法以及筛选长非编码rna和内源逆转录病毒来源长非编码rna的方法
CN116391028A (zh) 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
TW202246489A (zh) 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
JPWO2022191171A1 (enExample) 2021-03-09 2022-09-15
TW202305121A (zh) 2021-04-08 2023-02-01 日商武田藥品工業股份有限公司 Ｔ細胞活化方法
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
EP4332215A4 (en) 2021-04-28 2025-05-14 National University Corporation Tokyo Medical and Dental University Method for producing cells
CN113278686A (zh) * 2021-06-11 2021-08-20 扬州大学 一种研究dna甲基化调控重编程过程的方法
EP4410965A4 (en) 2021-09-27 2025-09-24 Univ Kyoto T LYMPHOCYTE PRODUCTION PROCESS
JPWO2023149555A1 (enExample) 2022-02-04 2023-08-10
EP4497822A4 (en) 2022-03-23 2026-03-18 Univ Kyoto PROCESS FOR THE PRODUCTION OF REGULATORY T LYMPHOCYTES
IL315122A (en) 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
EP4541882A4 (en) 2022-06-17 2025-10-15 Univ Kyoto METHOD FOR PRODUCING THYMIC EPITHELIAL CELLS
CN119546748A (zh) 2022-07-14 2025-02-28 千纸鹤治疗公司 细胞移植用纤维蛋白凝胶片
WO2024024742A1 (ja) 2022-07-25 2024-02-01 国立大学法人京都大学 霊長類の胎児卵巣細胞から卵胞を誘導する体外培養法
CN119744302A (zh) 2022-07-26 2025-04-01 国立大学法人京都大学 具有脱落结构的人工受体
CN120051562A (zh) 2022-08-05 2025-05-27 国立大学法人京都大学 用于产生心肌的方法
CN119698463A (zh) 2022-08-08 2025-03-25 希里欧斯株式会社 细胞团块的制造方法
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
EP4596675A4 (en) 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS
CN120112629A (zh) 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
WO2024071280A1 (ja) 2022-09-29 2024-04-04 国立大学法人京都大学 腎毒性評価方法
WO2024106444A1 (ja) 2022-11-16 2024-05-23 学校法人関西医科大学 着床促進薬とそのスクリーニング系
EP4678737A1 (en) 2023-03-03 2026-01-14 Kyoto University Method for producing primed pluripotent stem cells
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
WO2024242069A1 (ja) 2023-05-19 2024-11-28 国立大学法人京都大学 神経堤細胞の製造方法
CN121646636A (zh) 2023-06-02 2026-03-10 国立大学法人京都大学 T细胞祖细胞产生方法
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
EP4763975A1 (en) 2023-08-15 2026-06-24 Kyoto University Method for producing small intestine tissue
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
JPWO2025094915A1 (enExample) 2023-10-30 2025-05-08
CN122477277A (zh) * 2023-11-16 2026-07-28 科洛索生物科学有限公司 用于生成诱导多能干细胞的方法和组合物
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026123000A2 (en) 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Cytokine armored engineered innate lymphoid cells and related methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
WO1995003402A1 (en) * 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9517779D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9809178D0 (en) * 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
EP1129176A4 (en) 1998-11-09 2002-10-30 Es Cell Int Pte Ltd EMBRYONIC STEM CELLS
MXPA01007820A (es) * 1999-02-04 2003-06-19 Technion Res & Dev Foundation Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
AU2002242173A1 (en) 2001-02-15 2002-08-28 Whithead Institute For Biomedical Research Stem cell identification
US20020137460A1 (en) * 2001-03-08 2002-09-26 Howard Sun Universal multi-band (5 bands and more) keyless RF remote control unit using bluetooth radio module as the base
JP4183614B2 (ja) 2001-05-31 2008-11-19 伸弥 山中 Ｅｓ細胞特異的発現遺伝子
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
WO2003027277A1 (en) 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reporgramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
DE10162080A1 (de) * 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
GB0202149D0 (en) * 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0211904D0 (en) * 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
WO2004009758A2 (en) 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
ES2569780T3 (es) * 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
WO2005080598A1 (ja) * 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
SG150567A1 (en) 2004-03-23 2009-03-30 Akaike Toshihiro Pluripotent stem cell growing method
US20060148104A1 (en) 2004-10-29 2006-07-06 Massachusetts Institute Of Technology Detection of ion channel or receptor activity
AU2006243810B2 (en) * 2005-04-29 2012-06-07 Monash University A method for producing stem cells or stem cell-like cells from mammalian embryos
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
KR101004634B1 (ko) * 2005-08-01 2011-01-04 뉴포텐셜, 인크. 잠재력이 복원된 리프로그래밍된 세포의 제조
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2206724A1 (en) * 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
GB0615327D0 (en) * 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2008001391A2 (en) 2006-06-27 2008-01-03 Jawaharlal Nehru Centre For Advanced Scientific Research Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof
DK3399025T3 (da) * 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
US20120282229A1 (en) * 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) * 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
EP2268796A1 (en) 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
WO2009152529A2 (en) * 2008-06-13 2009-12-17 Whitehead Institute For Biomedical Research Nine Cambridge Center Programming and reprogramming of cells
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production

Also Published As

Publication number Publication date
US10093904B2 (en) 2018-10-09
US9714414B2 (en) 2017-07-25
US20150118755A1 (en) 2015-04-30
MX348010B (es) 2017-05-23
EP2626416A3 (en) 2013-12-18
MX2009010847A (es) 2010-04-27
RU2502799C2 (ru) 2013-12-27
JP2020014479A (ja) 2020-01-30
MX352541B (es) 2017-11-29
EP3878949B1 (en) 2025-06-04
JP2022031941A (ja) 2022-02-22
US9382515B2 (en) 2016-07-05
JP2018086017A (ja) 2018-06-07
CN101932705A (zh) 2010-12-29
EP3878949A1 (en) 2021-09-15
US20170342386A1 (en) 2017-11-30
AU2008236629B2 (en) 2014-03-06
CA2683056C (en) 2020-03-24
JP6934501B2 (ja) 2021-09-15
US20190241874A1 (en) 2019-08-08
US20110076678A1 (en) 2011-03-31
US20250188423A1 (en) 2025-06-12
JP2024024049A (ja) 2024-02-21
JP2017035113A (ja) 2017-02-16
AU2008236629A1 (en) 2008-10-16
EP2145000A1 (en) 2010-01-20
CA2683056A1 (en) 2008-10-16
JP2015051022A (ja) 2015-03-19
EP2145000A4 (en) 2010-05-05
CN105861443A (zh) 2016-08-17
JP2020014480A (ja) 2020-01-30
EP2626416A2 (en) 2013-08-14
WO2008124133A1 (en) 2008-10-16
RU2009140903A (ru) 2011-05-20
JP2010523117A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
US20250188423A1 (en) Reprogramming of somatic cells
JP2010528622A (ja) 体細胞から多能性細胞を生成する方法
JP2017525347A (ja) ｉＰＳ細胞への再プログラミングの増強
AU2024203525A1 (en) Reprogramming of somatic cells
CA2695522A1 (en) Method of nuclear reprogramming
AU2020213357B2 (en) Reprogramming of somatic cells
EP2501803B1 (en) Methods of enhancing pluripotentcy
HK40058787B (en) Reprogramming of somatic cells
HK40058787A (en) Reprogramming of somatic cells
HK1227936A1 (en) Reprogramming of somatic cells
Boyer DNMT3b's Role in Hematopoietic Stem Cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200204

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240710

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241004

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250217

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250226

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250430

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250430

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250430

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20260114

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20260305

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260305

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260305